Currently, two adenosine triphosphate (ATP)-competitive reversible FGFR inhibitors, infigratinib (BGJ398) and pemigatinib, have been approved by the American Food and Drug Administration (FDA) for iCCA patients with FGFR2 fusion/rearrangement who have progressed after first-line chemotherapy (Kang, 2021; Hoy, 2020). The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.